Lifting and material handling equipment company Terex (NYSE:TEX) reported revenue ahead of Wall Street’s expectations in Q2 CY2025, with sales up 7.6% year on year to $1.49 billion. The company’s full-year revenue guidance of $5.4 billion at the midpoint came in 1.2% above analysts’ estimates. Its non-GAAP profit of $1.49 per share was 6.5% above analysts’ consensus estimates.
XPO Inc. reports mixed Q2 2025 earnings with revenue slightly beating estimates at $2.08B, while EPS declines. Shares rise pre-market, but broader sentiment remains cautious.
Infrastructure solutions provider Quanta (NYSE:PWR) reported Q2 CY2025 results exceeding the market’s revenue expectations, with sales up 21.1% year on year to $6.77 billion. The company’s full-year revenue guidance of $27.65 billion at the midpoint came in 2.4% above analysts’ estimates. Its non-GAAP profit of $2.48 per share was 1.4% above analysts’ consensus estimates.
Nutanix (NTNX) aligns with Minervini's trend strategy and high-growth momentum, showing strong technicals, rising earnings, and breakout potential. A top pick for growth investors.
BorgWarner beats Q2 earnings, raises full-year guidance, and hikes dividend by 55%. Strong profitability and new contracts drive growth. Stock up 4.5% pre-market.
PBF Energy reported mixed Q2 2025 results, with revenue beating estimates but EPS missing. The company declared a $0.275 dividend amid operational challenges. Stock shows muted pre-market movement.
Norwegian Cruise Line (NCLH) posted mixed Q2 2025 results, missing revenue estimates but meeting EPS targets. Stock rose 7.7% on strong demand and reaffirmed guidance.
Cryptocurrency-focused companies Coinbase Global Inc. and Strategy Inc. which are due to report their second-quarter earnings after Thursday's market close, have seen their stock performances diverge significantly lately.
Integra LifeSciences (IART) Q2 2025 earnings beat revenue and EPS estimates, but shares dipped pre-market. Strong performance in neurosurgery and wound care segments drives growth.
TreeHouse Foods (THS) beats Q2 2025 earnings with EPS of $0.17, exceeding estimates by 63%. Adjusted net sales and EBITDA also outperform, driving a 3.45% pre-market stock gain. Strong operational execution boosts investor confidence.
TAL Education Group (NYSE:TAL) reported Q1 FY2026 results with $575M revenue, missing estimates, but EPS of $0.07 beat forecasts. Shares rose 10.8% pre-market.
SNDL Inc. beats Q2 2025 estimates with $244.99M revenue and $0.014 EPS, driving a 4.17% pre-market stock surge. Positive operating income signals growth in the competitive cannabis market.
Biotech company Biogen (NASDAQ:BIIB) beat Wall Street’s revenue expectations in Q2 CY2025, with sales up 7.3% year on year to $2.65 billion. Its non-GAAP profit of $5.47 per share was 41.3% above analysts’ consensus estimates.
Cigna Group (NYSE:CI) beat Q2 revenue estimates but slightly missed on EPS, reaffirming full-year guidance. Shares rose 4.4% pre-market as investors focused on growth.
Teleflex (NYSE:TFX) beats Q2 2025 estimates with $780.9M revenue and $3.73 EPS, driving a 15.9% pre-market surge. Strong growth in medical tech sector.
Exponent Inc (EXPO) excels with high profitability, strong cash flow, and steady growth, making it a top pick for long-term quality investors under the Caviar Cruise strategy.
KBR Inc. reported mixed Q2 2025 results with $1.95B revenue (up 6% YoY but below estimates) and $0.91 EPS (beating forecasts). Shares dipped as revenue miss offset EPS beat.
Railcar products and services provider Trinity (NYSE:TRN) fell short of the market’s revenue expectations in Q2 CY2025, with sales falling 39.8% year on year to $506.2 million. Its GAAP profit of $0.17 per share was 37% below analysts’ consensus estimates.
Today's focus centres on corporate earnings, critical economic data releases, central bank decisions on interest rates, and developments in trade negotiations ahead of the new U.S. tariffs set to take effect this Friday.
Electronic equipment provider Vontier (NYSE:VNT) reported Q2 CY2025 results beating Wall Street’s revenue expectations, with sales up 11.1% year on year to $773.5 million. Revenue guidance for the full year exceeded analysts’ estimates, but next quarter’s guidance of $750 million was less impressive, coming in 0.7% below expectations. Its GAAP profit of $0.62 per share was 1.9% above analysts’ consensus estimates.
Eaton Corp. (ETN) is a top dividend stock with strong profitability, financial health, and consistent dividend growth, making it ideal for long-term investors.
Engineered components manufacturer for critical industries ITT Inc. (NYSE: ITT) beat Wall Street’s revenue expectations in Q2 CY2025, with sales up 7.3% year on year to $972.4 million. Its non-GAAP profit of $1.64 per share was 1.8% above analysts’ consensus estimates.
A major U.S. Army contract and strong analyst ratings underpin the bull case for Red Cat stock, whose recent price dip presents a compelling opportunity.
Diversified healthcare company CVS Health (NYSE:CVS) reported Q2 CY2025 results topping the market’s revenue expectations, with sales up 8.4% year on year to $98.92 billion. Its non-GAAP profit of $1.81 per share was 23.9% above analysts’ consensus estimates.
Discover how Dorman Products (DORM) aligns with Peter Lynch's GARP strategy—steady growth, fair valuation, strong financials, and a solid market position in automotive aftermarket parts.
August could be a particularly strong month for the S&P 500, driven by earnings season and the growth outlook; this examines five buys investors should consider
While the Fed voted to maintain the Fed Funds rate at 4.25-4.50%, Michelle Bowman and Christopher Wallace cast dissenting votes in favor of reducing rates.
Healthcare tech company Omnicell (NASDAQ:OMCL) announced better-than-expected revenue in Q2 CY2025, with sales up 5% year on year to $290.6 million. On top of that, next quarter’s revenue guidance ($295 million at the midpoint) was surprisingly good and 3.2% above what analysts were expecting. Its non-GAAP profit of $0.45 per share was 66.7% above analysts’ consensus estimates.
